<DOC>
	<DOCNO>NCT00591188</DOCNO>
	<brief_summary>The aim study determine preliminary efficacy capecitabine interferon-alpha second-line interleukin-2 base regimens patient MRCC</brief_summary>
	<brief_title>Capecitabine Interferon-Alpha Metastatic Renal Cell Carcinoma Patients With Failure Interleukin-2 Based Regimens</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Histologically cytologically confirm renal carcinoma CTconfirmed metastatic site Must measurable disease , define ≥ 1 unidimensionally measurable lesion measure ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Disease progression IL2 Age 18 old ECOG performance status 13 Life expectancy ≥ 2 month WBC ≥ 3,000/mm3 Platelet count ≥ 100,000/mm3 Hemoglobin ≥ 7.5 g/dL Creatinine ≤ 1.5 mg/dL ( 2.0 mg/dL postnephrectomy patient ) Total bilirubin ≤ 1.5 mg/dL AST ≤ 3.0 time normal Alkaline phosphatase ≤ 2.5 time normal ( 10 time ULN presence bone metastasis ) Not pregnant nursing No history autoimmune No history serious cardiac arrhythmia , congestive heart failure , angina pectoris , severe cardiovascular disease ( i.e. , New York Heart Association class III IV ) No CNS metastases neurologic exam and/or MRI No history seizure disorder No local and/or systemic infection require antibiotic within 28 day prior study entry No malignancy Written inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>kidney cancer , capecitabine , interferon</keyword>
</DOC>